Initially small doses were used, but with increasing experience the dose was increased until reaching in each case what appeared to be the optimal level. Tables 2 and 3 give the details. The 7 cases treated for less than one month were withdrawn because of side-effects. At each visit patients were asked to indicate the severity of day pain, night pain and morning stiffness and to say whether they thought their condition had improved or deteriorated since the last visit. For objective evidence the number of inflamed joints and the grip strength were used in the physician's assessment of progress. The patient was asked about side-effects and blood was taken for laboratory examination.
Results
On the basis of the findings it was possible to produce the evaluation given in Table 4 , which shows that approximately two-thirds of the patients derived appreciable benefit from fenclofenac treatment. In at least 3 of the cases the benefit of the drug was further indicated by a considerable increase in the patients' symptoms when they had to stop the drug because of sideeffects. Side-effects (Table 5) The only side-effect of any significance in this series was the development of an allergic skin response. This took the form of an irritant erythematous rash in 6 patients. In a further 2 cases there was skin irritation and the drug was stopped in one of these. In neither case did a rash actually occur. One of the patients was able to continue the drug and the symptoms settled. In 5 of the cases with a rash it appeared within a few days of starting the drug and in the sixth instance it occurred when the dose was raised from 600 mg to 1000 mg a day because of a deterioration in the rheumatoid arthritis. It seems that the rash occurred more frequently when the administration of the drug was started at a high dosage such as 1200 mg a day than when the dose was gradually increased from a lower level. One patient complained of diarrhoea and had to stop the drug at one stage but his joints deteriorated so considerably that he restarted the tablets on his own initiative and found that he was gradually able to take them again without recurrence of his diarrhoea. One patient insisted that she could not take the tablets because they nauseated her.
No hematological abnormalities were noted.
The prothrombin time was slightly raised in a proportion of the cases but insufficiently to affect treatment. A variable non-progressive rise in blood urea was noted in 2 cases and did not continue when treatment was maintained. No other biochemical abnormalities were seen.
Withdrawals (Table 6) In addition to those cases withdrawn because of skin rash and irritation and the one who was unable to tolerate the tablets because of nausea, 2 patients defaulted from follow up, 2 patients were taken off the tablets because of an inadequate response and 2 patients stopped taking the tablets because their arthritis no longer required treatment.
Discussion
There are now available for clinical use a large number of non-steroidal anti-inflammatory analgesics. On the whole, at maximal dosage, they produce equivalent anti-rheumatic effects, although there may be some variation in efficacy and tolerance between individual patients. None seem more effective than the long-standing preparations of aspirin, phenylbutazone and indomethacin. What is required is a new drug showing the following features: (1) More effective at a nontoxic dose level. (2) Well tolerated on long-term medication.
(3) Easy to take and long-acting. (4) Inhibitory to the rheumatoid process as well as the resulting inflammation.
On the basis of this and other clinical trials it would appear that fenclofenac is approximately equally as effective as the standard dose regimes of similar drugs in relieving the pain of arthritis but that it is similarly not capable of coping with the severe inflammation of some cases of rheumatoid arthritis. Further comparative drug trials are needed to assess this more thoroughly.
The drug is well tolerated by the gastrointestinal tract and there seem to be no long-term problems. The only significant side-effect encountered was a skin rash which, when it occurred, tended to do so during the first few weeks of therapy. Should this side-effect not develop it would appear that the patient has a good chance of being able to take the drug indefinitely without ill effect. Further studies are needed to confirm this.
Twice daily dosage seems to be adequate and an evening dose provides good control of night pain and morning stiffness. The drug should, therefore, be easy to take. This series did not provide adequate information concerning inhibition of the rheumatoid process but in several cases there appeared to be a tendency for the titre of rheumatoid factor to drop during the course of treatment with fenclofenac. This aspect requires further evaluation.
Conclusions
On the basis of this clinical trial fenclofenac would appear to have a useful effect on the symptoms of arthritis and spondylitis and, as it is on the whole well tolerated and easy to take, it may prove a useful drug in the management of the rheumatic diseases.
DISCUSSION

Dr B M Ansell (Chairman) asked Dr Montoya to
open the discussion on the use of fenclofenac.
Dr H E Montoya (Indianapolis, USA) gave a preliminary report of a twelve-week open study in 30 patients with active rheumatoid arthritis. Of the 30 patients, 28 had completed the study; 2 of them had dropped out because of skin rash and, of the other 26, 23 were in a good to very good situation in terms of control of pain, reduction of morning stiffness and, related to this, the use of extra pain medication. Two other patients were reported as being fair and one was in poor condition, meaning no response at all. The dose had been 1200 mg for all of them on a four times daily schedule. There had been no problems with the gastrointestinal tract.
Dr P Hollingworth (Harrow) said that 5 patients suffering from sero-negative juvenile chronic polyarthritis had been treated with fenclofenac at 18 mg/kg body weight in lieu of any other nonsteroidal anti-inflammatory agent for periods of 1-5 months. One patient had developed a generalized maculopapular rash after one month, and the drug was discontinued. In the remaining 4 patients, clinical and functional assessments suggested acceptable control of the disease process.
Dr Berry said that not one of the studies had shown anti-inflammatory activity although all had shown analgesic effectiveness. He asked whether those who had used cachet-enclosed preparations had checked their bioavailability because he had had some problems along those lines himself.
Dr Loebl challenged the view that anti-inflammatory activity changed the prognosis in rheumatoid arthritis. It might mean that patients got more pain control or less stiffness, but he thought that to differentiate artificially between analgesic and anti-inflammatory effect might be overdoing it.
Dr Pritchard, on the same topic of anti-inflammatory versus analgesic, said it had been noticed by the end of his trial that the patients who really did extraordinarily well on fenclofenac were those who had had the disease only for a few weeks or months, at which stage one would have expected to observe the anti-inflammatory effect of the drug most readily.
In patients who had had the disease for some years, however, and had actual damage to the joints, fenclofenac did not appear to be much better than any other drug.
Dr Goldberg, in reply to Dr Berry's point about the bioavailability, said that both disintegration tests and standard dissolution tests had been carried out and showed that there was no significant prolongation in the release-time of the drug if the tablets were encased in cachets. These tests had been done in vitro, and to date they had not carried out a bioavailability study.
Dr Ansell asked Dr Berry what evidence he would like to see to prove that a drug was anti-inflammatory.
Dr Berry said he would like to see a long-term double-blind trial study showing shrinkage of joint size and reduction of morning stiffness as one of the major considerations in addition to a spectrum of experimental animal data. Dr Ansell did not think that one could prove anti-inflammatory effects by one clinical measurement.
Dr Goldberg said he did regard shrinkage in joint size as an objective measurement and felt it could therefore be regarded as a measurement of antiinflammatory activity under the conditions of an open study.
He also regarded a fall in ESR as another objective measurement of anti-inflammatory activity and this had also been demonstrated in the open study.
